Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
申请人:Valeant Pharmaceuticals International
公开号:US07960436B2
公开(公告)日:2011-06-14
This invention provides compounds of formula I
where Ar1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR3R4 group is situated ortho to the NHC(═X) group; n=1 or 2; X═O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof.
These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.
SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS
申请人:Chen Huanming
公开号:US20110207812A1
公开(公告)日:2011-08-25
This invention provides compounds of formula I
where Ar
1
is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR
3
R
4
group is situated ortho to the NHC(═X) group; n=1 or 2; X=O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof.
These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.
Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
申请人:Chen Huanming
公开号:US20080146661A1
公开(公告)日:2008-06-19
This invention provides compounds of formula I
where Ar
1
is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR
3
R
4
group is situated ortho to the NHC(═X) group; n=1 or 2; X═O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof.
These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.